منابع مشابه
Coagulation assays.
Case 1: Mr F, a 75-year-old man with diabetes, was admitted with non–ST-segment-elevation acute coronary syndrome. In addition to other medications, he is receiving 1 mg/kg enoxaparin every 12 hours. He is scheduled for cardiac catheterization later in the afternoon. Earlier this morning, his activated partial thromboplastin time (aPTT) was 30 seconds. How should his anticoagulants be managed? ...
متن کاملEffect of Fondaparinux on Coagulation Assays
● Context.—Fondaparinux, a factor Xa inhibitor, is approved for thromboprophylaxis after orthopedic surgery and for treatment of venous thromboembolism. It may also be efficacious, safe, and cost-effective for other patients; thus, more widespread use of fondaparinux is likely. The effect of fondaparinux on coagulation testing needs to be thoroughly examined. Objective.—To report the effects of...
متن کاملInfluence of coagulation and anticoagulant factors on global coagulation assays in healthy adults.
It remains unclear how coagulation and anticoagulant factors influence global coagulation assays such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation assay (TGA). We measured PT, aPTT, coagulation factor and protein levels, and TGA parameters (lag time, endogenous thrombin potential [ETP], and peak thrombin) in 252 apparently healthy adults. Vitam...
متن کاملPediatric reference intervals for seven common coagulation assays.
References 1. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med 1997;336:1014–6. 2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1993; 340:115–26. 3. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148–50. 4. Li J-J, Fang C-H. C-Reactive protein is not ...
متن کاملFacts and artefacts of coagulation assays for factor Xa inhibitors.
Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of thromboembolic disorders; of these, rivaroxaban, apixaban and edoxaban (DU-176b) are in the most advanced stages of development. Rivaroxaban is approved in several countries for the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2005
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.104.478222